By Cheriko A. Boone, Abraham Johnson, and Richard Jefferys In a 1989 article by Dr. Anthony Fauci, “AIDS — Challenges to Basic and Clinical Biomedical Research” — which preceded Treatment Action Group’s founding by just a few years — he…
On November 16, 2022, please join TAG, INPUD and AfroCAB for our webinar “Community Mobilization to Ensure Health Systems’ Readiness for Long-Acting Therapies” at 8:00 a.m. EST / 02:00 p.m. CET / 05:30 IST.
As public health leaders, researchers, and civil society activists acting in solidarity with communities affected by tuberculosis (TB), we are dismayed by the continued global backslide in progress against history’s oldest pandemic.
Storytelling is a tool that can help build understanding, support discussions between members of affected communities and other stakeholders, and aid in the identification of important issues and potential solutions. The storyboards on this page describe the experiences of people…
As the global Long-Acting Technologies Community Advisory Board (LAT CAB) representing vast civil society networks, and people living with and affected by malaria, HIV, tuberculosis, and the hepatitis C virus (HCV) across the world, we welcome the efforts leading to the development of an investigational long-acting injectable (LAI) formulation of ivermectin to fight malaria transmission, mdc-STM currently in preclinical stage, and developed by MedinCell.
Treatment Action Group (TAG) and Médecins Sans Frontières (MSF) Access Campaign are pleased to launch the Principles for Access to Multi-disease Molecular Diagnostics.
We, the undersigned civil society and community-based organizations, welcome the announcement by Unitaid and its partners that they have reached an agreement with Lupin Limited and Macleods Pharmaceuticals to introduce two formulations of rifapentine at competitive prices.
Four years after the Medicines Patent Pool (MPP) and AbbVie came to agreement on a voluntary license authorizing MPP to sublicense G/P to generic manufacturers to ensure commercialization in low- and middle-income countries, generic G/P is not available anywhere.
Pipeline Report provides an overview of research and provides an overview of research and development of innovations for diagnosing, preventing, treating, and curing HIV, hepatitis C virus (HCV), and tuberculosis (TB).
In 2021, the Global Tuberculosis Community Advisory Board (TB CAB) celebrated its tenth anniversary of advocating for community engagement in research and improved access to TB prevention, treatment, and diagnostic technologies.